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ABSTRACT
Zika Virus (ZIKV) is a mosquito-transmitted flavivirus that usually causes no symptoms
to mild febrile in humans, and it has been regarded as an insignificant pathogen to public
health. However, recent outbreaks of ZIKV infection have revealed that ZIKV can cause
severe neurological effects in adults, such as Guillain-Barre Syndrome (GBS), and in
infants whose mothers acquired the virus during pregnancy, causing Congenital Zika
Syndrome (CZS). Currently, no approved vaccine is available and there is a critical need
to develop an effective and safe vaccine. While most vaccine developmental strategies
target the viral prM-E protein of ZIKV, we aimed to create an attenuated ZIKV by
inserting several different nucleotide lengths into the 5’ untranslated region (UTR) of the
viral genome. We generated a viable mutated ZIKV virus (Z7) was after inserting a 50-nt
sequence into the 5’UTR. We then characterized Z7 by comparing growth kinetics in vivo
replication by using qPCR and immunostaining assays in cell cultures. We also measured
the infectivity and immunogenicity of Z7 in Ifnar1-/- mice. We found that this mutated
virus developed a lower viremia compared to WT ZIKV control but induced a similar
level of antibody response. Importantly, one dose of Z7 inoculation can protect the mice
from a secondary high dose of ZIKV infection in Ifnar1-/- mice. Together, these results
suggest that we have successfully developed an attenuated ZIKV strain, which induces
protective immune responses against ZIKV infection in mice.
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To determine the viral growth kinetics, 5x105 Vero cells were plated in 6-well plates and
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DMEM and allowed the virus to attach for 1 hour at 37°C. Cells were collected on days
2, 3, 4, 5 and 6 post-infection. After collection and qPCR was performed to measure the
expression levels of ZIKVE. The qPCR results showed that while Z1 peaked after longer
incubation than Z7, Z1 replicated at much higher levels than Z7 consistently at all the
tested time points (Figure 4.1A and B). To exclude the possibility of an effect of dose
variation, 5x104 cells were plated in 24-well plates and infected with MOI of 0.05 of
viruses for one hour at 37°C. Cells were collected on days 2 and 4 p.i. for qPCR, and the
results showed a decreasing trend of Z7 replication (Figure 4.1C ). To measure the
difference of ZIKV E protein expression of the two viruses, 5x105 Vero cells were
infected with the viruses of 100 FFA and 10 FFA in duplicate for 1 hour and allowed to
incubate for 3 to 5 days previously determined by Focus Forming Assay staining. These
results showed that Z1 had more clear foci as well as higher numbers of foci as compared
to Z7, which had very faint staining but countable foci in the 10 FFA wells (Table 4.3).
Z7 was incubated for 5 days whereas Z1 only needed 3 days for FFA staining, suggesting
that Z7 produces a lower amount of viral proteins over a longer time than Z1, indicating
Z7 has a lower replication rate compared to Z1 the WT ZIKV strain. further indicating Z7
has a lower replication rate compared to Z1 the WT ZIKV strain. .................................. 37
4.6 Ifnar1-/- Mice Generates a Lower Viremia to Z7 Infection ..................................... 39
We next wanted to test if Z7 replicates more slowly in an animal model. Eight-week-old
and four-week-old Ifnar1-/- mice were infected intraperitoneally with 300 PFU of each
virus in 100 µL of DMEM. Mice were bled once for three days post-infection and the
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CHAPTER I INTRODUCTION
1.1 Flavivirus
Flaviviruses are enveloped, positive sensed, single-stranded RNA viruses that
belong to the family Flaviviridae, which also includes the genera Hepacivirus, specific to
Hepatitis C virus, and Pestivirus, which holds several agriculturally important viruses that
infect stock animals (Yun & Lee, 2017). The first virus classified in the genus Flavivirus
was the Yellow Fever virus (YFV) in 1928, but the fever associated with that virus was
known in the Caribbean and Americas since the early 17th century. Its relationship to
being vectored by mosquitos was established by the Yellow Fever Commission in 1897
(Holbrook, 2017). Throughout the 20th and 21st centuries, many medically important
flaviviruses have been increasing in incidence and re-emerging across the tropical and
subtropical areas of the world, including the emergence of West Nile virus (WNV) in the
United States in 1999, Dengue virus (DENV) in the subtropics on yearly cycles, and Zika
virus (ZIKV) in Brazil in 2015 (Holbrook, 2017; Musso & Gubler, 2016). WNV has
spread throughout the globe except Antarctica and causes 24,000 neurological disease
cases and 2,300 deaths in the U.S. (Holbrook, 2017) (Kaiser JA, Barrett ADT. 2019).
DENV has four different serotypes that all can cause Dengue Fever, Dengue
Hemorrhagic Fever, and Dengue Shock Syndrome through a mechanism called antibodydependent enhancement, which has made vaccine development difficult (Barrows et al.,
2018; Garcia-Blanco et al., 2016). Japanese encephalitis virus (JEV) is another genus
member that causes severe neurological disease, however, there has been an effective
vaccine approved by the FDA (Barrows et al., 2018; Prevention, 2019). ZIKV is a newly
emerging virus in the Americas as of 2015-6 and has been implicated in causing a febrile
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like illness in most patients but microcephaly in neonates and Guillain-Barré Syndrome
(GBS) in some adults (Musso & Gubler, 2016; Shankar et al., 2017; Yun & Lee, 2017).
Except for YFV and JEV, there are no effective and safe vaccines against most of the
flaviviruses.

1.2 Genome
Flaviviruses have an 11kb long, positive sense, single-stranded RNA genome. The
genome is comprised of a 5’ untranslated region (UTR), an open reading frame that
translates into a polyprotein, and a 3’UTR. The polyprotein is then cleaved by the cellular
and viral enzymes into ten functional proteins, i.e. three structural proteins, capsid (C),
pre-membrane (prM), and envelope (E) proteins that aid in the formation of the viral
particles and the non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B,
and NS5) that provide crucial viral enzymes for multiplication of the viral genome (Bai et
al., 2019; Barrows et al., 2018). The UTRs of the flavivirus genome have been an areas
of live attenuated vaccine research in recent years due to the specific structures held
within crucial for RNA-dependent RNA polymerase (RdRp) used in viral replication,
with each having a slightly “sticky end” function that allows them to circularize the
genome during replication (Ng et al., 2017).

Figure 1.1 Flavivirus Genome and Polyprotein (Yun & Lee, 2017)
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1.3 Flavivirus Lifecycle and Genome Replication
In general, flaviviruses enter the cell through receptor-mediated endocytosis via
cell surface receptors that engage with the viral E protein. In the acidic environment of
the late endosome, the membranes of the virus and endosome fuse, releasing the viral
genome into the cytoplasm. The viral genome is translated within the cytosol using
cellular and viral enzymes into a single polyprotein, which cleaved by viral and host
proteases into 10 functional proteins needed for viral genome replication and virion
assembly (Barrows et al., 2018).
To begin translation, host factor eIF4E recognizes the methyl cap and the highly
structured 5’UTR. The host factor recruits ribosomes and begins the genome translation
process; however, the 3’UTR is also critically important to translation as it has the
downstream UAR codon that aides in proper enzyme binding after interacting with the 5’
UTR AUG codon (Brinton & Basu, 2015). This is accomplished by cyclization of the
genome, in which the 5’ UTR secondary structures interact with the 3’ UTR (Barrows et
al., 2018; P. Li et al., 2018).
As the initial translation is occurring in the cytosol, the entire complex is moving
toward the endoplasmic reticulum (ER) of the cell. The three viral proteins, the capsid,
prM, and E proteins, are structural proteins to be built into virions. The detailed functions
of NS1 during viral replication are not fully understood, but NS1 is vital to replication
and localize to the sites of RNA synthesis, as does NS2. NS3, however, is highly active in
genome replication as protease, an ATPase-driven helicase, and a 5’ RNA triphosphatase,
which is used before NS5 RNA uncapping. NS4A and B are components of the
replication complex, and NS4A is thought to specifically aid in protein scaffolding and
15

NS4B interacts with NS3 to aid in replication. NS5 is arguably the most active viral
protein, acting as the RNA dependent RNA polymerase (RdRp) and methyltransferase
that caps the replicated viral genome (Barrows et al., 2018).
Once these NS proteins are processed, the virus transcribes its genome into
complementary, negative-sense RNAs that serve as templates for the positive viral
genome replication. Once enough genomic RNA has been replicated, the structural
proteins are recruited and the virions begin to assemble and egress through the ER, taking
its membrane to form the viral membrane. The virions are then fully matured as they
egress from the ER to the Golgi apparatus through an acidic pH change that separates the
pr- and M portions of the prM allowing for the release of pr upon entering the neutral pH
of the cytoplasm. The mature virions are then secreted through exocytosis (Bai et al.,
2019; Barrows et al., 2018; Yun & Lee, 2017).
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Figure 1.2 Flavivirus Life cycle of Flavivirus (Shankar et al., 2017)

1.4 Zika Virus
Zika virus (ZIKV) was first discovered in the Zika forest of Uganda in 1947 in a blood
sample from a rhesus monkey (MacNamara, 1954). The first human transmission was
detected in Nigeria in 1952 and isolated from Aedes aegypti mosquitos a year later
(Musso & Gubler, 2016). During the 20th century, ZIKV spread from Africa to Asia and
the oceanic states. Usually, ZIKV infection leads to either an asymptomatic or low-grade
febrile illness that is described as a “summer flu” in humans (Musso & Gubler, 2016).
The symptoms include fever, headache, conjunctivitis, and rash which last for about a
week. However, during 2007 the Yap Island outbreak, the virus seemed to cause much
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more severe symptomatic diseases, with the addition of rash and arthritis (Counotte et al.,
2018; Musso & Gubler, 2016). Also, during the outbreak in French Polynesia in 2013-14,
the new association of GBS in usually healthy adults developed, followed by the
association of microcephaly in neonates during the 2015-2016 outbreak in Brazil
(Counotte et al., 2018). In French Polynesia, the usual rate of GBS in adults was 1-3 per
100,000 population per year. During the ZIKV outbreak, the cases of GBS rose to 3-10
cases of GBS per 100,000 people between 2009 to 2012 (Musso & Gubler, 2016). GBS
is an autoimmune disease in which the periphery nervous system (PNS) is attacked
mononuclear and polynuclear immune cells causing acute flaccid paralysis in patients
(Leonhard et al., 2019). It is caused by an instigating infection that triggers the immune
system to attack the PNS. It is a serious illness that progresses rapidly, usually within two
weeks, to affect the autonomic nervous system, with 20% of cases needing mechanical
ventilation (Leonhard et al., 2019). The recovery period of GBS is often very long (6
months or more) and can be incredibly painful, but with only supportive treatment
available (Leonhard et al., 2019).
Except for GBS in adults, ZIKV has also been documented as a causative agent of
newborn microcephaly. In Brazil, the average number of microcephaly cases were 150200 per year before 2015, but this number rose to 1,761 cases in 2015 alone (Castro et al.,
2018; Musso & Gubler, 2016). At the end of the initial outbreak in January 2016, the case
numbers rose to 3,893 (Musso & Gubler, 2016). According to the most recent counts
from the Centers for Disease Control and Prevention (CDC), there are 2,751 cases of
CZS reported to the Brazilian Ministry of Health as of 2017 (Castro et al., 2018). It has
been shown that when pregnant mothers contracted the virus within the first trimester in
18

pregnancy, there is a higher incidence to have newborn babies with CZS (Guevara &
Agarwal-Sinha, 2018; Marques et al., 2019). The CZS consists of microcephaly,
neurological lesions, ophthalmological development issues, and even hearing loss in
some cases (Guevara & Agarwal-Sinha, 2018; Marques et al., 2019). When children with
CZS grow older, more complications such as epilepsy and sleep disturbance may arise
(Marques et al., 2019).
Due to the significant health concerns that ZIKV is causing and there is no
specific treatment available, the development of an effective and safe vaccine is critically
needed.

1.5 Transmission of ZIKV
ZIKV is primarily transmitted by the bite of the Aedes species of mosquito,
especially the Yellow Fever mosquito Aedes aegypti, but it is also transmitted by blood
transfusion, via placenta from pregnant mother to fetus, as well as by sexual contact
(Kauffman & Kramer, 2017; Musso & Gubler, 2016; Shankar et al., 2017; Yun & Lee,
2017). Due to the prevalence and near world-wide distribution through international
travel, ZIKV has been able to flourish on nearly every continent within the tropics
(Musso & Gubler, 2016). ZIKV has now become a public health threat due to the
increase in international travel and development of sexual transmission, especially
considering that most people are asymptomatic when infected with the virus, leading to a
need for increased research and prevention measures (Shankar et al., 2017).
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1.6 Current Antiviral and Vaccine Development against ZIKV
Currently, there are no approved treatments for ZIKV except supportive care in
the case of symptomatic infection, which includes fever management and supplementing
liquids. There are several groups currently working on antiviral development, following
two main directions: direct-acting antivirals (DAAs) or host acting antivirals (HAAs)
(Garcia et al., 2017; Saiz, 2019). DAAs focus on targeting the proteins and complexes of
the viruses themselves, whereas HAAs target host-virus complexes that are used in the
initial replication of the virus (Saiz, 2019).
For DAAs there are multiple targets used for drug development ranging from
envelope binding to polymerase, methyltransferase, and protease inhibitors (Saiz, 2019).
Some drugs are already well known effective drugs against RNA or DNA viruses, such
as Favipiravir (a purine synthesis inhibiting NS5 polymerase) and Viperin (pyrimidine
synthesis inhibitor and protease inhibitor) (Saiz, 2019). HAA development mostly
focuses on the viral life cycle and the host proteins recruited for that purpose. The most
relevant to this project is Silvestrol, which targets eukaryotic initiation factor-4A
(eIF4A), which interacts at the 5’UTR by regulating translation through the ribosomes
(Elgner et al., 2018). This drug was shown to decrease ZIKV replication in vitro (Elgner
et al., 2018). While there is promising data for these approaches, the primary question is
whether or not these drugs will be safe for pregnant women to use, meaning each must
have rigorous testing in vitro, in vivo, and clinical trials. It will be a long time if and when
these drugs can be on the market (Garcia et al., 2017; Saiz, 2019; Shankar et al., 2017).
There are several different approaches to vaccine development: purified
inactivated vaccines, nucleic acid vaccines, virus-like particle (VLP) vaccines, subunit
20

vaccines, recombinant vaccines, therapeutic vaccination, live attenuated vaccines (Saiz,
2019). There are currently over 50 different vaccine candidates entering phase 1 or 2
clinical trials across the globe, but only one or two from each category of developmental
strategy will be discussed here (Durbin & Wilder-Smith, 2017).
Purified inactivated vaccines are those that contain completely inactivated
versions of the pathogens (Hajj Hussein et al., 2015). One of the most successful
inactivated vaccines is the polio vaccine developed by Jonas Salk. In the case of ZIKV,
there are several inactivated vaccines in development, with one formalin-inactivated
ZIKV vaccine already in double-blind, placebo trials in the U.S. (Saiz, 2019). While
inactivated vaccines are generally considered to be safe vaccines, they often need several
doses of boosters to ensure total immunity, which could prove difficult in the low
income, rural areas of the tropics where ZIKV has become prevalent.
Nucleic acid vaccines are originally composed of non-replicating vectors
in a lipid that resulted in the generation of gene products in muscle cells (Vogel & Sarver,
1995). The immune system then creates antibodies against the proteins translated by the
host. Currently, both DNA and RNA can be used to develop these vaccines, and
currently are the most popular route to take for developing vaccines for ZIKV, usually
using the prM/E gene as the primary target sequence in both RNA and DNA studies.
PrM/E is what cells recognize when mounting the immune defense (Annamalai et al.,
2019; Griffin et al., 2017; Saiz, 2019). Recent prototypes for ZIKV DNA vaccines seem
to be trigger efficient cellular and humoral responses in non-human primates (NHP)
(Saiz, 2019).
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Other approaches to vaccine development are virus-like particle (VLP) vaccines
and subunit vaccines These vaccines use the ZIKV prM/E protein to trigger an immune
response through expressing the virus surface proteins instead of using the whole viral
genome, allowing the immune system to mount a response without risking viral
replication (Alarcon et al., 1999; Saiz, 2019; Shankar et al., 2017). This allows VLPs to
be used even in pregnant women, making them very important tools for vaccination.
Subunit vaccines are made by one part of a pathogen protein to trigger immunity,
however, there are very few ZIKV subunit vaccines being developed, and none have
made it to a clinical trial (Lin et al., 2018).
Live attenuated vaccines are vaccines that genetically altered versions of a
pathogen but not completely killed. These vaccines are generally thought to be the most
efficient at producing both humoral and cellular immune responses with only one dose of
vaccination, making them the most highly effective vaccine. Several live attenuated
vaccines are currently within phase I or II trials around the world, showing that targeting
viral genes like E or NS1, deleting portions of NS genes or the 3’ UTR, or a combination
of the two, can effectively attenuate ZIKV (Annamalai et al., 2019; Griffin et al., 2017;
Shan et al., 2017). However, the studies on ZIKV 5’UTR have primarily focused on
studying the effect of editing on genome cycling and infectivity, and no studies are using
the resulting decreased replication as a possible route for vaccine development.
Therefore, this project aims to show if 5’UTR mutations can effectively decrease
infectivity, but still induce antiviral immunity in a mouse model.
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Current ZIKV vaccine candidates in clinical trials (Lin et al., 2018)

1.7 The 5’ UTR and the 3’ UTR Elements
The 5’ and 3’ UTRs have several elements that are critical for virus replication,
specifically so that the virus can complete the genome cycling needed for genome
replication in the cytoplasm (Goertz et al., 2018; X. F. Li et al., 2010). For both UTRs,
there is a cyclization sequence on each region that is complementary to the other, leading
to an RNA “panhandle” structure when the genome is properly cyclized, with the
functional genome of the virus forming a loop (Goertz et al., 2018). These sequences are
fairly short, only ten to sixteen bases long when compared to the ~100 and ~400 bases of
the entire 5’ and 3’ UTR respectively, but are highly conserved across the flavivirus
genus (Goertz et al., 2018; Villordo & Gamarnik, 2009).
The other elements used by both UTRs are the self-complementary regions that
form stem-loop (SL) and dumbbell structures (DB) structures that are crucial structures
for the binding of host factors and viral RdRp that recruits ribosomes to the site of
translation (de Borba et al., 2015; Filomatori et al., 2011; Goertz et al., 2018; X. F. Li et
al., 2010). In the 3’ UTR, these secondary structures help form pseudoknots, which aid
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against viral degradation by host proteases. These pseudoknots are also implicated in the
formation of subgenomic flavivirus RNA (sfRNAs), which are formed when XRN1
attack the genome (Goertz et al., 2018). There have been G-quadruplexes detected in the
3’ UTR on the (+) strand of the ZIKV genome. While the function of this region has not
been elucidated, it is important to include in the formation of any mutant 3’ UTR as it
may impede the correct genome cyclization of the flavivirus(Goertz et al., 2018). The
roles of 3’ UTR makes a good target candidate in drug the development of attenuated
ZIKV strains (Schneider & Wolfinger, 2019).
The 5’UTR, however, is much simpler in composition in comparison to the 3’
UTR. ZIKV genome, specifically, has three RNA structures: two stem-loops, SLA and
SLB, and the start codon and the capsid hairpin. SLA is the primary structure used for
initial viral replication; however, the other two are used to bind to the 3’UTR for genome
circularization (Brinton & Basu, 2015; Elgner et al., 2018; P. Li et al., 2018; Ng et al.,
2017). It is also the shorter UTR, having only around 100 nucleotides per genome.
However, as previously stated, it is to the 5’UTR that the host enzymes bind when
initializing translation in the cytoplasm. It has also been shown that the 5’UTR of ZIKV
and DENV have some Internal Ribosome Entry Site (IRES) capabilities that allow for
translation control in mammalian cells, but to what functional extent these IRES regions
have is still to be discovered(Song et al., 2019).

1.8 Animal Models of ZIKV Infection
Type I Interferon (IFN) receptor knockout mice (Ifnar1-/-) were developed in the early
1990s to study DENV. This is because, unlike in humans, the NS5 protein of flaviviruses
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do no degrade STAT-2 in mice. STAT-2 is a part of the IFN-regulated JAK-STAT
pathway, so creating these knock-outs allows for similar pathway reactions to human
infection (Krishnakumar et al., 2019; Paul et al., 2018). These Ifnar1-/- mice are the most
commonly used animal model for ZIKV infection, but others focus on knocking out the
STAT proteins or IFN Regulatory Factors (IRFs) (Krishnakumar et al., 2019). Nonhuman primates (NHP) are also used for ZIKV studies, considering that they are the
animals of sylvatic transmission. NHP primates show similar symptoms in ZIKV to
humans, including those relating to pregnancy (Pierson & Diamond, 2018).
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CHAPTER II -SIGNIFICANCE, HYPOTHESIS, AND INNOVATION

2.1 Significance
Zika Virus has recently emerged as a world health concern due to its ability to cause
severe neurological syndromes. In healthy adults, it can cause a slight flu-like illness or
no symptoms at all. However, the virus can vertically transmit through the placenta of a
pregnant woman and cause the child to be born with Congenital Zika Syndrome, which
includes microcephaly, eye development, and ear development issues. In some adults,
ZIKV infection can cause Guillain-Barre Syndrome, an autoimmune syndrome that
attacks the peripheral nervous system. This study aims to show if editing the 5’ UTR can
lead to attenuation of ZIKV, it may be used as a ZIKV vaccine candidate. This research
can lead to advancements in vaccine development for flaviviruses in general by showing
that there are other genome targets to create effective attenuation.

2.2 Hypothesis
Vaccine development is a major task in the control of ZIKV infection. Most ZIKV
vaccine development strategies are to target the prM-E, the non-structural proteins, and
the 3’UTR, and there are none that focus on the 5’UTR, which is essential for both RdRp
recognition as well as eIF4E to initiate ribosomal translation. In eukaryotic translation,
ribosomes scan from the methyl-cap for an AUG start codon and stall at areas with stable
secondary structures, such as stem-loops, as the ribosomes have to “melt” these structures
to continue down the RNA strand. A previous report showed that by adding differing
lengths of stem-loops in eukaryotic cells, translation was slowed considering the length
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of the GC-rich structures (Babendure et al., 2006). While this 5’UTR insertion method
has been used to both attenuate translation in different eukaryotic systems (Endo et al.,
2013; Kozyrev et al., 2007), it has not been applied to viral research previously.
Therefore, we hypothesize that 5’ UTR insertion should reduce ZIKV replication and
translation without changing the viral antigenic epitopes, thus the attenuated viruses may
be used as vaccine candidates. We tested this hypothesis using the following aims.

2.2.1 Specific Aim 1: Generate Viable Attenuated ZIKV by modifying 5’ UTR
ZIKV attenuation has been achieved by the deletion of nucleotides in the 3’ UTR. We
hypothesized that by adding nucleotides to the 5’UTR, viral replication and protein
translation would be lessened. In this aim, we will generate mutant ZIKV by transfecting
plasmids or PCR products containing the 5’UTR mutant ZIKV genome into Vero cells.
We will measure the infectivity of the mutant ZIKVs in vitro.

2.2.2 Specific Aim 2: Assess the infectivity and immunogenicity of the mutant
ZIKVs in mice
To test if the mutated viruses to replicate slower in a mouse model, we will infect Ifnar1-/mice with wild-type and mutated virus to measure viremia after infection. We also will
assess the antibody response to the mutant ZIKV infection. Finally, we will examine if
the primary immunity protects a secondary high dose of ZIKV infection.
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2.3 Innovation
ZIKV is a pathogen that is linked to severe birth defects leading to CZS in babies and
neurological autoimmune disease (GBS) in adults, causing a significant world health
concern. While there are several reports on antiviral drug and vaccine development, they
are targeting replication of the virus by the prM/E dimer, the non-structural proteins, and
the 3’UTR. This thesis is novel in that we are developing a new virus attenuation strategy
by modifying ZIKV 5’UTR, which has not previously studied in any viral researches. In
addition, this strategy may also be applied to generate other attenuated viruses, such as
WNV, DENV, and SARS-Cov-2, which is currently causing the pandemic COVID-19
diseases.
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CHAPTER III – Experimental Approaches

3.1 Ethics and Biosafety Statement
All animal care and experiments were conducted according to the Guide for the Care and
Use of Laboratory Animals approved by The University of Southern Mississippi (USM)
under the IACUC protocol # 16031002.1. All the experiments involving live ZIKV were
performed by certified personnel in biosafety level 2 and 3 laboratories following
standard biosafety protocols approved by the USM Institutional Biosafety Committee.

3.2 Virus Stock, Cells, Plasmid, and Animals
The original ZIKV plasmids (Cambodian strain) were generously provided by Dr. Peiyong
Shi at the University of Texas Medical Branch (UTMB). The 5’UTR mutant ZIKV
plasmids were developed by Dr. Faqing Huang at the University of Southern Mississippi.
The rescued viruses were grown in Vero cells (ATCC CCL-81) in Dulbecco’s Modified
Eagles Media (DMEM, Life Technologies) supplemented by 10% Fetal Bovine Serum
(FBS) and 1% penicillin/streptomycin (P/S). Cells and viruses were grown at 37°C and
5% CO2. Breeding pairs of type I interferon receptor-deficient (Ifnar1-/-) mice were
purchased from the Jackson Laboratory (Bar Harbor, ME). Mice were housed under
standard conditions in the animal facility at USM.

Plasmid Transfection and Virus Collection
Plasmids were transfected into Vero cells using Lipofectamine 3000 reagent
according to the user’s manual. Briefly, Vero cells were plated at 2.5 x105 cells/well in a
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6 well plate and allowed to incubate for 24 hours. 500 ng of the plasmid in serum- and
antibiotic-free medium to 30 µl of the DNA solution, 5.5 ul of Lipofectamine 3000 was
diluted into 30 µl of the same medium used in the other dilution. The DNA and
Lipofectamine 3000 solutions were mixed immediately and incubated for 15 minutes at
RT. The mixture was added to 1 ml of fresh media and added to the cells. The cells were
then incubated for 4 to 6 hours to which another 1ml of the medium was added, and the
cells were incubated for 5 days. The cell culture supernatant was then collected and
stored at -70°C.

3.3 Viral Infection
Cells were infected by either direct supernatant or virus diluted in DMEM. Virus
containing medium was added to cells and allowed to incubate for 1 hour at 37°C and 5%
CO2. Viral medium was then removed, and new medium was added. Cells were incubated
over time in the same conditions as initial incubation.

3.4 qPCR of ZIKV detection
Cells or mouse blood was collected using the RNeasy Mini Kit (Qiagen) and converted
into the first-strand cDNA using the iSCRIPT™ cDNA synthesis kit (Bio-Rad). Probebased PCR (Bio-Rad) qPCR was performed using iTAQ polymerase™ supermix to detect
ZIKV-E gene and mouse β-Actin and SYBR Green™ supermix to detect Vero cell β-Actin
(Acharya et al., 2016)
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3.5 qPCR of viral quantification
Viral copy numbers were determined using a modified version of the protocol previously
described by the Bai lab (Acharya, Paul, Anderson, Huang, & Bai, 2015). Briefly, 300 µL
of virus-containing media were treated with 75 units of RNase A for one hour at 37°C.
TRI-Reagent (Molecular Research Center, Inc) was used to stop the reaction, and after 5
ug tRNA was added, RNA was extracted according to the manufacturer’s instructions.
cDNA and qPCR were performed as described above.

3.6 Focus Forming Assay (FFA)
FFA experiments were performed in Vero cells according to previously described protocols
(Paul et al., 2015). Briefly, cells were plated at 5x105 cells per well and allowed to attach
overnight at 37°C with 5% CO2. The next day, viruses were serially diluted into DMEM
and allowed to infect for 1 hour at 37°C. Viral containing media was removed and FFA
overlay media with 1% methylcellulose was added. Plates were incubated for several days
equal to peak viral titer collection time determined by growth curves. On the day of the
peak viral replication, the overlay media was removed, and the monolayers were
immunologically stained using flavivirus-specific 4G2 antibody and Histomark®
TrueBlue™ Peroxidase System.

3.7 Animal Studies
Ifnar1-/- mice were infected by intraperitoneal injection with 300 PFU (plaque-forming
units) of either wild-type or mutated ZIKV. Starting day 1 post-infection (p.i.),
approximately 200 L of blood was collected for three days. Mice were then bled again
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at day 24 p.i. to measure if ZIKV is still present in the blood. On day 42 p.i., the mice
were challenged with a high dose of ZIKV strain PRVABC59 and bled, then euthanized
to collect spleens and livers on day 2 post the secondary infection to measure ZIKVE
RNA by qPCR.

3.8 Enzyme-Linked Immunosorbent Assay (ELISA)
ZIKV infected Ifnar1-/- mice were bled 24 d.p.i after isoflurane anesthesia. Blood was
spun at 2,000 g for 10 minutes to prepare plasma. The plasma was then stored at -70°C
until used. Anti-ZIKV E IgG was measured in the plasma by using the Mouse Anti-ZIKV
Envelope IgG ELISA kit (Alpha Diagnostic, International).

3.9 Statistical Analysis
Data analysis was performed using Mann-Whitney U-test using GraphPad Prism software
(version 6.0) with p<0.05 being considered as significant.
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CHAPTER IV – RESULTS
4.1 Development and Structure of the Mutant 5’UTRs
To develop the new ZIKV mutants, Dr. Huang first designed new 5’UTR
sequences containing 18, 38, or 50 additional GC-rich nucleotide sequences at the end of
the original sequence but before the start codon (AUG) of ZIKV. He used the program
SnapGene Viewer to develop the sequences, which are detailed below along with their
future designations and theoretical structures (Table 4.1), using the sequence detailed in
the paper “Reverse Genetics of Zika Virus” by Shan et al. Below, the bolded sequences
are the insertions provided by Dr. Huang. All structural images were obtained by using
the website http://unafold.rna.albany.edu/?q=mfold/RNA-Folding-Form. All three of
these insert sequences were added to the original sequence and theoretically folded, as
shown in Table 4.1. These figures were chosen as a representative structure of the insert,
however, for Z3-Z7, there were as many as four different secondary structures that have
similar thermal stability as indicated by the folding energy ∆G In short, the theoretical
structures showed that as the number of inserted nucleotides increases, the number of
structures on 5’ end of the UTR also increased. Meanwhile, the folding energy also
increases, indicating higher potential to inhibit translation initiation. This is promising as
cellular translation enzymes depend on stem-loop structures to begin replication and
ribosomes will stall when engaged with additional stem-loop and hairpin structures. This
supports the hypothesis that editing the 5’ UTR will decrease the efficacy of viral
translation and replication, thus attenuating the virus.
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Z1 (Wild
Type ZIKV)

Z3 (18-nt
insert)

Z5 (38-nt
insert)

Z7 (50-nt insert)

AGTTGTTGAT
CTGTGTGAAT
CAGACTGCGA
CAGTTCGAGT
TTGAAGCGAA
AGCTAGCAAC
AGTATCAACA
GGTTTTATTTT
GGATTTGGAA
ACGAGAGTTT
CTGGTC

AGTTGTTGAT
CTGTGTGAAT
CAGACTGCGA
CAGTTCGAGT
TTGAAGCGAA
AGCTAGCAAC
AGTATCAACA
GGTTTTATTTT
GGATTTGGAA
ACGAGAGTTT
CTGGTCCGTA
CGAGCGCAG
GTGC

AGTTGTTGATC
TGTGTGAATC
AGACTGCGAC
AGTTCGAGTTT
GAAGCGAAAG
CTAGCAACAG
TATCAACAGG
TTTTATTTTGG
ATTTGGAAAC
GAGAGTTTCT
GGTCCGACCA
CGGCCGGAA
ACGGCCGTG
GTCGCGCAG
GTGCC

AGTTGTTGATCTGT
GTGAATCAGACTGC
GACAGTTCGAGTTT
GAAGCGAAAGCTA
GCAACAGTATCAAC
AGGTTTTATTTTGG
ATTTGGAAACGAGA
GTTTCTGGTCCGTT
CCAACCACTGACT
CGAAAGAGTCAGT
GGTTGGAACGCGC
AGGTGCC

Theoretic
al
Structure

Genome
Sequence
in DNA
Format

Table 4.1 Wild Type and Mutant ZIKV Theoretical Structures and Genome
Sequences
The inserted DNA sequences in the plasmids are in red. The predicted RNA structures were
produced in the RNAFold website. All the plasmids were developed and provided by Dr.
Huang’s lab at USM.

4.2 Detecting ZIKV Mutants in vitro
To test if the transfection yielded infectious viral particles, 100 µl of supernatant
from each plasmid transfection plus 900 µl of fresh medium was inoculated to 5x105
Vero cells/well in a 6-well plate and incubated at 37°C with 5% CO2 for 1 hour. The
supernatant containing medium was removed and the cells were rinsed with PBS, then 2
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ml of fresh DMEM supplemented with 10% FBS and 1% P/S was added to each well.
After three days of incubation, the supernatant was collected and stored at -70°C, and the
cells were collected in TRI-Reagent™. Total RNA was then extracted from the cells
according to the manufacturer’s instructions and used to make cDNA using the Bio-Rad
iSCRIPT™ cDNA synthesis kit. ZIKV-E was then measured via probe-based PCR by
Bio-Rad (Figure 4.1). Both Z5 and ZIKV-7 can replicate in Vero cells after five days of
incubation, however, they show decreased replication compared to the wild-type virus.

A Negative Control

B Lipofectamine Control

E Z5
D Z3
Figure 4.2 CPE caused by ZIKV mutants

C Z1 (WT)

F Z7

Images were taken at 20x magnification using a Lecia DM IL LED inverted light microscope on 4
d.p.i. A. Negative control (medium only). B. Lipofectamine control (medium with Lipofectamine
reagent). C. Z1 WT with no 5’ UTR insert. D. Z3 viral mutant with an 18-nt 5’ UTR. E. Z5 viral
mutant with a 38-nt 5’UTR insert. F. Z7 viral mutant with a 50-nt 5’ UTR insert.
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4.3 Cytopathic Effects of Mutant ZIKVs Compared to WT ZIKV
We test if these plasmids generated ZIKVs can cause a similar level of cytopathic effect
(CPE) to Vero cells. The second generation of ZIKVs was incubated with Vero cells for 4
days. The images show that wild-type (WT) ZIKV caused CPE to Vero cells, while there
was no sign of CPE induced by the mutant ZIKVs (Fig 4.1 A-F). This result indicates that
mutant ZIKVs may replicate slower than the WT ZIKV.

4.4 Quantification of Mutant Viruses by qPCR
To quantify the amount of infections particles yielded by the transfection, we tried
to use a plaque assay method. While Z1 produced plaques, Z5 and Z7 did not form
plaques with Vero cells. We switched to the PFU-equivalent method, which uses qPCR
to detect the copy numbers of viral genes in the viral containing medium. We also
included a sample of WT ZIKV of a different strain for which we had a PFU/ml and used
it to back-calculate PFU-equivalent concentrations of the viruses (Acharya et al., 2015).
Due to the low titers of Z5 by qPCR (Table 4.2), we decided to test our hypothesis with
only Z7 in my thesis.
Sample

Titer detected by PCR
Genes/ml
(300µL original sample)
ZIKV (PRVABC59)
2999
10000
Z1
4432
14777
Z5
0.2719
0.9066
Z7
896.5
2988.4
Table. 4.2 Quantification of the viral genomic copies by qPCR
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4.5 Z7 Mutant Has a Lower Replication Rate In Vitro
To determine the viral growth kinetics, 5x105 Vero cells were plated in 6-well
plates and were infected with 100 µL of virus-containing DMEM diluted with 900 µL of
fresh DMEM and allowed the virus to attach for 1 hour at 37°C. Cells were collected on
days 2, 3, 4, 5 and 6 post-infection. After collection and qPCR was performed to measure
the expression levels of ZIKVE. The qPCR results showed that while Z1 peaked after
longer incubation than Z7, Z1 replicated at much higher levels than Z7 consistently at all
the tested time points (Figure 4.1A and B). To exclude the possibility of an effect of dose
variation, 5x104 cells were plated in 24-well plates and infected with MOI of 0.05 of
viruses for one hour at 37°C. Cells were collected on days 2 and 4 p.i. for qPCR, and the
results showed a decreasing trend of Z7 replication (Figure 4.1C ). To measure the
difference of ZIKV E protein expression of the two viruses, 5x105 Vero cells were
infected with the viruses of 100 FFA and 10 FFA in duplicate for 1 hour and allowed to
incubate for 3 to 5 days previously determined by Focus Forming Assay staining. These
results showed that Z1 had more clear foci as well as higher numbers of foci as compared
to Z7, which had very faint staining but countable foci in the 10 FFA wells (Table 4.3).
Z7 was incubated for 5 days whereas Z1 only needed 3 days for FFA staining, suggesting
that Z7 produces a lower amount of viral proteins over a longer time than Z1, indicating
Z7 has a lower replication rate compared to Z1 the WT ZIKV strain. further indicating Z7
has a lower replication rate compared to Z1 the WT ZIKV strain.
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Figure 4.3 Z7 Mutant has a lower replication rate in vitro
Growth curve results for Z1 wild type (A) and Z7 (B) performed on Vero cells on
day 6 p.i.. (C) Vero cells were infected with plasmid derived viruses at MOI (0.05)
for one hour at 37°C. ZIKVE gene was quantified by qPCR.

Figure 4.4 Immunostaining of the Z1 and Z7 infected Vero cells
Results of 4G2/TrueBlue Peroxidase staining after a one-hour infection with Z1 or Z7. 5x105 Vero
cells were allowed to incubate for 3 days (Z1) or 5 days (Z7). Images were taken by a Lecia M165
FC microscope. Images A. and D. Negative control (no virus added) showing no TrueBlue
peroxidase staining. Images B. and E. Cells were treated with 100 PFU-equivalent of either Z1 (B)
or Z7 (E). Images C. and F. Cells were treated with 10 PFU-equivalent of either Z1 (C.) or Z7 (F).
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4.6 Ifnar1-/- Mice Generates a Lower Viremia to Z7 Infection
We next wanted to test if Z7 replicates more slowly in an animal model. Eightweek-old and four-week-old Ifnar1-/- mice were infected intraperitoneally with 300 PFU
of each virus in 100 µL of DMEM. Mice were bled once for three days post-infection and
the viremia was measured via qPCR. Both sets of mice showed a decrease in the amount
of Z7 as compared to Z1, confirming Z7 has attenuated infectivity in vivo as in vitro.

Figure 4.5 Z7 Has a Lower Viremia that Z1 in Ifnar1-/- mice
Four-week-old (A) or eight-week-old (B) Ifnar1-/- mice were infected with 300 PFU-equivalent either
Z1 or Z7 in 100 µL of DMEM. ZIKVE in blood was measured via qPCR and normalized to mouse
cellular beta-actin on each day. The results were compared using Mann-Whitney U-test with p<0.05
as significant.
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4.7 Z1 But Not Z7 killed Four-week-old Ifnar1-/- Mice
To test mouse susceptibility to mutant ZIKV (Z7) infection, we measured the
survival in the 4-week old mice. Mice were observed every day and any changes in
vitality were noted. While no changes were observed between Z1- and Z7-infected 8week-old Ifnar1-/- mice, 2 of 3 of Z1 (n=3) 4-week-old mice died, while all of the Z7
infected mice (n=3) survived during the observation period (Figure 4.5).

Survival of 4-week-old Ifnar1-/- mice

Percent survival

100

Z1 (n=3)
Z7 (n=3)

50

0

0

10

20

30

Days elapsed

Figure 4.6 Four-week-old Ifnar1-/- Mice Survived Z7 Infection
Mice were observed daily for survival for 28 d.p.i. Z1 group (n=3), and Z7 (n=3). Percent
survival was compared using log-rank test, p > 0.05.

4.8 Z7 Induces anti-ZIKV IgG Response
To test if Z7 could induce a comparable immune response in Ifnar1-/- mice, we
measured the anti-ZIKV IgGs in the plasma from both sets of infected mice by ELISA.
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We found that Z7 infection induced a similar level of IgG with Z1. These results
suggested that although Z7 attenuated in replication, it still triggers anti-ZIKV IgG
production (Fig. 4.7).

Figure 4.7 ELISA Results of anti-ZIKV IgG
Mice were infected with 300 PFU i.p. with either Z1 or Z7 and allowed to overcome infection.
Mice were bled at either 24 (A) or 25(B) d.p.i to collect plasma from each experimental group.
U/ml calculated by comparison to a standard curve of anti-ZIKV E IgG provided in the ELISA
kit.

4.9 Immunity to Z7 Protects Against Secondary high dose of ZIKV Infection
To test whether the immunity to Z7 inoculation could provide sufficient
protection against secondary high dose of ZIKV infection, we challenged the previously
infected mice with a high dose (1x105 PFU/ml) of ZIKV strain PRVABC59 and
sacrificed the mice on day 2 post-infection. The blood, liver, and spleen samples were
collected, and qPCR was performed to detect ZIKVE genes. However, all samples were
below the detection threshold for ZIKVE, showing that the both Z1 and Z7 infected mice
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developed sterile immunity that sufficiently protects the mice from a high dose of ZIKV
infection, suggesting that Z7 may be used a vaccine candidate for further tests.

ZIKV PRVABC59 in 8-week-old Ifnar1-/- mice
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Figure 4.8 Lack of Detection of ZIKVE after the Secondary Infection
Mice were injected i.p. with 1x105 ZIKV strain PRVABC59. On 2 d.p.i., blood, liver, and
spleen were collected for qPCR detection of ZIKVE. All samples were below the detection
threshold of ZIKV by qPCR.
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CHAPTER V -DISCUSSION
ZIKV was once considered to be a non-important human pathogen until the recent
outbreaks in the twenty-first century (Yun & Lee, 2017). However, as these outbreaks
revealed that ZIKV can induce GBS and the CZS, the need for effective vaccination and
anti-viral medication has been on the forefront of ZIKV research since 2016 (Durbin &
Wilder-Smith, 2017; Lin et al., 2018). However, development for vaccines is challenging
due to the multitude of requirements to be considered for safety and efficacy and must be
able to protect both mothers and fetuses (Durbin & Wilder-Smith, 2017; Lin et al., 2018;
Saiz, 2019).
Due to the rapid advancements of plasmid and genome editing technology,
scientists are now able to target not only the most immunogenic protein of ZIKV (prME), but also the non-structural proteins that are crucial to viral replication and assembly
(Mazeaud, Freppel, & Chatel-Chaix, 2018; Shan et al., 2017). These proteins are also the
targets of anti-viral drug development, which also goes through the rigorous testing of the
FDA’s clinical trials. Even with the testing of previously approved drugs against ZIKV,
such as ribavirin and suramin, there are no currently approved drugs or vaccines for
ZIKV (Saiz, 2019).
The flavivirus 5’ and 3’ UTR are both critical for viral genome cyclization after
eIF4E engages the 5’ end (Ng et al., 2017). This cyclization then move the genome to the
ER, where ribosomes translate the initial positive sense genome into the polyprotein that
is cleaved by cellular and viral enzymes, starting the active replication of the viral
genome (Bidet & Garcia-Blanco, 2018). There have been DENV studies early in the
2000s in which deletions and substitutions have been made in both UTRs showing
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variability in replication, however, the current focus of research on the UTRs of
flavivirus is on the function of the regions in the creation of subgenomic flavivirus RNAs
(sfRNA) (Goertz et al., 2018; Mazeaud et al., 2018; Sirigulpanit, Kinney, &
Leardkamolkarn, 2007).
In this study, we found that by inserting nucleotides to the 5’ UTR (Z7), ZIKV
replication was reduced in vitro when compared to wild type ZIKV (Z1), following the
trend established by the previously mentioned DENV UTR studies (Sirigulpanit et al.,
2007). We then transfected four plasmids, one wild type (Z1) and three mutants of
differing 5’ UTR inserts (Z3, Z5, and Z7) into Vero cells and allowed to grow until CPE
was observed, usually around four days. We found that one generation after initial
transfection, Z3 did not replicate in Vero cells after 5 days as Z5 and Z7, and so was
disregarded for further tests.
After the initial transfection, we quantified the growth kinetics of the two mutants
Z5 and Z7 in vitro. However, we were unable to propagate Z5 after the initial transfection
experiment, so we continued the project focusing on Z7. After infecting Vero cells with
similar the same amount of virus-containing supernatant, we found that Z7 replicated
much slower and reached its peak earlier compared to Z1 (Fig 4.3 A and B). This was
confirmed by other in vitro studies (Fig 4.3 C) as well as qPCR viral genome
quantification, which confirmed the consistent decreased trend of growth of Z7. (Table
4.2). These results show that Z7 has a lower replication rate in Vero cells than Z1 by
qPCR. Next confirmed this conclusion at the protein levels. Using serial dilution to
infect with the same number (PFU-equivalent) of infectious particles, we were able to see
stronger peroxidase staining in the Z1 as compared to Z7, with Z1 being incubated for 3
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days and Z7 being incubated for 5 days before the infected cell foci could be detected.
The FFA results suggest that it takes longer for Z7 to produce detectable cell foci than
Z1, and the ZIKVE protein detected is at lower concentrations than Z1. These data further
demonstrate Z7 is attenuated in viral genome replication and protein translation in cell
culture.
Next, we predicted that Z7 would also have slower replication in an animal
model. We used Infar1-/- mice, in which type I interferon signaling is deficient, to test our
hypothesis (Grant et al., 2016). Age did show a difference in the amount of virus
detected, however, we noticed that Z7 induced decreased viral burden in both 4-week old
mice and 8-week old mice. This is a promising phenotype, considering in vivo test
vaccinations using the DENV 5’ UTR studies also showed a lower viremia in human
patients (Sirigulpanit et al., 2007). Another promising phenotype we observed during the
in vivo experiments was the death of two of the Z1 infected 4-week-old mice as
compared to the Z7 mice on days 7 and 8. The survival results further confirm that Z7 has
an attenuated infectivity in animals.
We were able to conduct a few long-term immunological studies with the Ifna1r-/mice groups. Approximately three weeks after primary infection, we bled the mice to
measure their IgG antibody production by ELISA. Anti-ZIKV antibodies most
commonly reactive against the envelope dimers of the virus, however, they can be made
against the NS1 protein as well (Rey, Stiasny, Vaney, Dellarole, & Heinz, 2018;
Vidarsson, Dekkers, & Rispens, 2014). The assay we used showed that Z7 induced the
mouse anti-ZIKV IgG immune response against the envelope protein in both young and
older mice like Z1. These results indicate that Z7 is immunogenic and can induce anti45

ZIKV immunity. This was confirmed by the results showing Z7-infected mice are
completed resistant to a high dose of ZIKV strain PRVABC59 challenge. Besides the
antibody response, Z7 is expected to induce effector and memory T cell responses as well
since the viruses still can infect and replicate in cells. Therefore, the T cell responses to
Z7 should be examined in the continuation of this project.
Our data showed that the addition of GC-rich sequences before the AUG codon
was able to reduce viral production both in vitro and in vivo. It has been shown that the
addition of secondary structures near the start codon of eukaryotic cells can inhibit the
translation of mRNA by ribosomes, specifically thermodynamically stable secondary
structures with ∆G ≥ -50 kcal/mol (Babendure et al., 2006). It was also shown that
location in relation to the methyl cap of the mRNA had an inhibitory effect on translation
with structurally stable inserts. And the opposite was also true for unstable inserts, and
the further away from the methyl cap and closer to the start codon, the less translation
occurred. Using the same concept, we developed three inserts for the 5’UTR whose first
5’ nucleotide were at the same distance from the methyl cap of ZIKV genome. We
predicted that the length of the insert itself would negatively corelate with the efficiency
of viral translation and replication. However, our results showed that Z3 with the shortest
(18-nt insert) didn’t produce viable viral particles in two independent experiments. This
could due to the 18-nt insertion dramatically changes the folding of Z3 5’UTR.
According to the theoretical structures by RNAFold, the 5’UTR of Z3 exhibits an almost
liner structure made of two long stem loops compared with that of Z1 (WT), which has a
Y-shaped stem loop (SLA) and a small stem loop (SLB) (Figure 4.1). The major
structural change in 5’UTR may block its binding to 3’UTR and abolish the cyclization
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of the viral genome, which are essential to the viral genome replication by the RdRp. In
contrast, Z3 and Z7 that have a 38- or 50-nt insert only slightly alter the structures of
5’UTR by adding an extra stem loop, which may only slowdown the ribosome binding to
the start codon rather than entirely blocking the genome cyclization and replication.
Consistent to the structure predication, our experiment results indicated that the 5’UTR
modifications of Z5 and Z7 produced viable but attenuated viral particles. These results
support our hypothesis that 5’ UTR insertion reduces ZIKV translation and replication,
thus produces attenuated viral particles.
In conclusion, the addition of GC-rich nucleotides to the 5’ UTR can inhibit
replication on both RNA and protein levels of ZIKV in vitro and in vivo. Importantly, Z7
can induce efficient protective immunity against a high dose of ZIKV infection with a
current circulating strain in humans. Collectively, my results show that targeting the 5’
UTR by adding ribosome-stalling secondary structures may be a new strategy to develop
attenuated ZIKV strains and Z7 could be used as a vaccine candidate for further testing.
This new strategy may also be applied to generate other attenuated viral vaccine
candidates.

47

CHAPTER VI -CONCLUSION AND FUTURE DIRECTIONS
6.1 Conclusions
In this study, we showed that the mutant Z7 ZIKV virus has lowered
amplification in vitro and in vivo. This phenotype was measured at both RNA and
protein levels, and both in vitro and in vivo. It also induced anti-ZIKV-E IgG antibodies
in comparable amounts to the WT virus, as well as protected Ifnar-/immunocompromised mice against secondary infection of ZIKV. Therefore, Z7 may be
a viable candidate for further testing and development.

6.2 Future Directions
Further study into the immunological response of Ifnar1-/- mice to infection with
Z7 is needed. The in vitro studies should be repeated at higher MOIs to test the growth
kinetics at higher infectious doses, as well as more protein studies such as Western Blot.
The in vivo studies should be repeated with larger mice numbers to determine if the
differences are statistically significant.
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